Onyx Seeks Suitors After Rejecting Amgen’s Bid

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

Most Recent Videos

How Apple Conquered China Market: Bloomberg West (01/30)
45:40 - Jan. 30 -- Full episode of "Bloomberg West." Guests: GGV Capital's Hans Tung, Strategic Analytics' Neil Mawston, Evercore ISI's Ken Sena, CKE Restaurants CEO Andrew Puzder, Boost VC CEO Adam Draper and Zebra Technologies' Jill Stelfox.
  • Should Amazon Spin Off Its Growing Cloud Business?
  • TripAdvisor's Top Pick: Chicago's Langham Hotel
  • Dan Marino: Roger Goodell Has Done a Really Good Job